IL-13 x TSLP
Asset
Bispecific antibody targeting IL-13 and TSLP for Type 2 inflammatory airway disease control.
- Stage
- Phase 1
- Modality
- Antibody
- Target
- TSLP
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Asthma
Phase 1, prnewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets3
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.